In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Mark Lowdell, CSO & Co-Founder, INmuneBio Inc

Vishwas Seshadri, CEO & Director, Abeona Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.